

H₄octapa-Trastuzumab: Versatile Acyclic Chelate System for ¹¹¹In and ¹⁷⁷Lu Imaging and Therapy

Eric W. Price,^{†,§} Brian M. Zeglis,[‡] Jacqueline F. Cawthray,^{†,§} Caterina F. Ramogida,^{†,§} Nicholas Ramos,[‡] Jason S. Lewis,^{*,‡} Michael J. Adam,^{*,§} and Chris Orvig^{*,†}


[†]Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, Canada, V6T 1Z1

[§]TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 2A3

[‡]Department of Radiology and Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10065, United States

S Supporting Information

ABSTRACT: A bifunctional derivative of the versatile acyclic chelator H₄octapa, *p*-SCN-Bn-H₄octapa, has been synthesized for the first time. The chelator was conjugated to the HER2/*neu*-targeting antibody trastuzumab and labeled in high radiochemical purity and specific activity with the radioisotopes ¹¹¹In and ¹⁷⁷Lu. The *in vivo* behavior of the resulting radioimmunoconjugates was investigated in mice bearing ovarian cancer xenografts and compared to analogous radioimmunoconjugates employing the ubiquitous chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The H₄octapa-trastuzumab conjugates displayed faster radiolabeling kinetics with more reproducible yields under milder conditions (15 min, RT, ~94–95%) than those based on DOTA-trastuzumab (60 min, 37 °C, ~50–88%). Further, antibody integrity was better preserved in the ¹¹¹In- and ¹⁷⁷Lu-octapa-trastuzumab constructs, with immunoreactive fractions of 0.99 for each compared to 0.93–0.95 for ¹¹¹In- and ¹⁷⁷Lu-DOTA-trastuzumab. These results translated to improved *in vivo* biodistribution profiles and SPECT imaging results for ¹¹¹In- and ¹⁷⁷Lu-octapa-trastuzumab compared to ¹¹¹In- and ¹⁷⁷Lu-DOTA-trastuzumab, with increased tumor uptake and higher tumor-to-tissue activity ratios.



INTRODUCTION


Radiometalated bioconjugates possess an inherent modularity that can prove extremely useful in the design and construction of agents for nuclear imaging and therapy. Indeed, they contain a set of four distinct chemical components that can be swapped systematically to tune the properties and functions of the whole: the radiometal can be exchanged to harness isotopes with different decay characteristics; the chelator can be altered to accommodate different radiometals; the nature of the covalent linkage between the chelator and the biomolecule can be changed to take advantage of different types of conjugation chemistry; and, of course, the biomolecule itself can be replaced in order to change the targeting properties or pharmacokinetics of the construct.^{1–7} In clinical practice, the use of different isotopes with a single targeting vector becomes especially important in pretherapy imaging and dosimetry studies, procedures in which an agent bearing an imaging radioisotope is used for scouting scans prior to radiotherapy using the same vector labeled with a therapeutic nuclide. Two isotopes that are ideally suited for this purpose are ¹¹¹In, a cyclotron produced radiometal (¹¹¹Cd(*p,n*)¹¹¹In) for SPECT imaging (*t*_{1/2} ~2.8

days), and ¹⁷⁷Lu, a reactor produced therapeutic radiometal (¹⁷⁶Lu(*n, γ*)¹⁷⁷Lu) that emits β[−] particles as well as γ-rays (*t*_{1/2} ~6.6 days).⁸

Due to their exceptional specificity and affinity, antibodies have emerged as extremely promising biomolecules for the delivery of radioactive payloads to cancerous tissues.^{9,10} However, antibodies are not without their limitations as radiopharmaceutical vectors. For example, while they are generally considered robust *in vivo*, antibodies can become damaged or break down when subjected to the elevated temperatures required by many radiometal chelation reactions.¹¹ As a result, the choice of a chelator for a radioimmunoconjugate becomes particularly critical. In any radiopharmaceutical, the purpose of the chelator is to sequester the radiometal such that the isotope remains attached to the targeting vector at all times, resisting spontaneous demetalation as well as transchelation to serum proteins. Macrocyclic chelators, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-

Received: May 16, 2013

Published: July 31, 2013

Chart 1. Structures of Some Selected Chelators^a

^aChelators used or discussed in this work, including two based on the pyridinecarboxylate scaffold that were developed in our laboratory: the promising ^{67/68}Ga chelator H₂dedpa and H₄octapa, the nonbifunctional variant of the chelator p-SCN-Bn-H₄octapa used in this work.

acetic acid (DOTA; Chart 1), have long been staples of radiochemical research. They are versatile and are generally more kinetically inert than acyclic chelators, primarily due to their constrained geometries and partially preorganized coordination sites.^{12–19} One unfortunate and restrictive property of macrocycles like DOTA, however, is that heating (40–90 °C) and extended reaction times (30–180 min) are typically required for quantitative radiolabeling, conditions that can be incompatible with antibodies and other biomolecules.^{12–26} Acyclic chelators offer improvements in this regard, but not without cost. The acyclic chelator diethylenetriamine-tetraacetic acid (DTPA), for example, exhibits much faster reaction kinetics than DOTA and can radiolabel with a variety of radiometals quantitatively in a matter of minutes at ambient temperature. However, it is not nearly as stable *in vivo* as its macrocyclic counterparts.^{14,15,27–29}


Thus, choosing a radiometal chelator for an antibody conjugate requires a delicate balancing act. An immunoconjugate bearing a macrocyclic chelator, such as DOTA, can require extended incubations at elevated temperatures—often at the expense of antibody stability or immunoreactivity—in order to achieve suitable radiochemical yields; however, a radioimmunoconjugate bearing an acyclic chelator, such as DTPA, risks the unintentional release of the radiometal *in vivo*, an especially pressing problem considering the long pharmacokinetic half-life of many antibodies.^{8,10,19–22,26–28} It thus becomes clear that a versatile chelator that combines the thermodynamic stability and kinetic inertness of macrocyclic chelators with the facile radiolabeling of acyclic chelators could prove tremendously valuable in the synthesis and development of novel radioimmunoconjugates.

Herein, we report the synthesis, characterization, and *in vivo* validation of p-SCN-Bn-H₄octapa, a bifunctional, versatile, acyclic chelator that can be labeled rapidly at room temperature (RT) and exhibits significant thermodynamic stability and kinetic inertness with ¹¹¹In and ¹⁷⁷Lu. This ligand has evolved out of our laboratory's extensive study of acyclic chelators based

on the pyridinecarboxylate scaffold (Chart 1).^{30–38} Members of the versatile “pa family” of chelators, including H₄octapa, H₂dedpa, H₃decapa, and H₂azapa, cover nearly all of the current medically relevant radiometals.^{30–38} H₄octapa specifically has demonstrated high *in vitro* and *in vivo* stability and rapid radiolabeling kinetics with ¹¹¹In. Further, comparisons with ¹¹¹In-DOTA have revealed that H₄octapa possesses much more facile radiolabeling kinetics, can be labeled in higher specific activity, undergoes less fluxional isomerization in solution, and exhibits comparable stability *in vitro* and *in vivo*.³³ A major hurdle during this work, however, has been the cumbersome syntheses of the chelators.^{30–36} As a result, in the investigation at hand, we report the construction of the bifunctional p-SCN-Bn-H₄octapa via a vastly improved synthetic protocol. More importantly, we have employed the HER2/*neu*-targeted antibody trastuzumab as a model system for the *in vitro* and *in vivo* validation of ¹¹¹In-octapa- and ¹⁷⁷Lu-octapa-based radioimmunoconjugates in a murine model of ovarian cancer as well as the comparative evaluation of these radioimmunoconjugates to those employing the more traditional macrocyclic chelator DOTA.

RESULTS AND DISCUSSION

Synthesis and Characterization. In order to properly evaluate the potential of H₄octapa for use in biomolecular radiopharmaceuticals, we first sought to develop a highly efficient synthesis of a novel bifunctional variant of the versatile acyclic chelator, p-SCN-Bn-H₄octapa (Scheme 1), which had never been synthesized before. Like many bifunctional chelators, we have utilized the versatile and enantiopure starting material L-4-nitrophenylalanine.^{29,30,33} While the *N*-benzyl-based protecting group chemistry we have previously reported for the synthesis of nonbifunctional H₄octapa proved adequate for the construction of the bare chelator, the requisite vigorous hydrogenation conditions resulted in poor yields and were completely incompatible with the synthesis of bifunctional derivatives based on 4-nitrophenylalanine.^{30,33} Consequently,

Scheme 1. Improved Synthesis of Chelators Utilizing Nosyl Protection Chemistry^a

^a(a): (i) THF, NaHCO₃, 2-nitrobenzenesulfonyl chloride (2.2 equiv), RT, 24 h, 87%; (ii) DMF, Na₂CO₃, methyl-6-bromomethylpicolinate (2.2 equiv), 50 °C, 24 h, 95%; (iii) THF, thiophenol (2.2 equiv), K₂CO₃, RT, 72 h, 91%; (iv) MeCN, Na₂CO₃, *tert*-butylbromoacetate (2.2 equiv), 50 °C, 24 h, 92%; (v) 6 M HCl, reflux, 24 h, 66%. (b) (i) THF, NaHCO₃, 2-nitrobenzenesulfonyl chloride (2.2 equiv), 50 °C, 24 h, 74%; (ii) DMF, Na₂CO₃, *tert*-butylbromoacetate (2.2 equiv), 50 °C, 24 h, 88%; (iii) THF, thiophenol (2.2 equiv), K₂CO₃, RT, 72 h, 89%; (iv) MeCN, Na₂CO₃, methyl-6-bromomethylpicolinate (2.2 equiv), 50 °C, 24 h, 96%; (v) 5 mL of (1:1) glacial acetic acid:3 M HCl, Pd/C (20 wt %), H₂ (g) balloon, RT, 1 h; (vi) 6 M HCl, reflux, 24 h; (vii) thiophosgene in DCM (15 equiv), 3 M HCl, RT, 24 h, 50% over steps v–vii.

we revamped the synthesis to utilize the 2-nitrobenzenesulfonyl amide (nosyl) protecting group, a change that has significantly improved the synthesis of H₄octapa (**5**) and has made the synthesis of *p*-SCN-Bn-H₄octapa (**12**) feasible.^{30,33,36,39–41} Specifically, the switch to the nosyl protecting group has dramatically increased the cumulative yield of H₄octapa (**5**) from ~10–12% to ~45–50% over five synthetic steps.³³ Further, using this strategy, the bifunctional variant *p*-SCN-Bn-H₄octapa—previously inaccessible using *N*-benzyl protection chemistry—can now be routinely produced with cumulative yields over 7 steps of ~25–30%. To our knowledge, only a few previous publications have utilized the 2-nitrobenzenesulfonyl amide (nosyl) amine-protecting group for the synthesis of chelating or imaging agents.^{39–43}

Compared to the challenging syntheses of bifunctional macrocycles like *p*-SCN-Bn-DOTA, this streamlined route to *p*-SCN-Bn-H₄octapa should be of significant utility. The bulky nature of the nosyl protecting groups is admittedly atom inefficient; however, their use results in a reduced number of purification steps (compounds **1**, **2**, and **8** can be purified via crystallization), greater yields, and, most relevantly, the

accessibility of *p*-SCN-Bn-H₄octapa. The final three steps in the synthesis of *p*-SCN-Bn-H₄octapa are performed sequentially without purification due to the high polarity and difficult separation of the intermediates, and the final molecule is purified via reverse-phase HPLC chromatography.

Following synthesis, the HCl salt of pure H₄octapa was successfully metalated via incubation with indium perchlorate³³ [In(ClO₄)₃] and lutetium chloride [LuCl₃] to form quantitatively coordinated complexes. Further, all of the new chelators and their metal complexes were fully chemically characterized using ¹H NMR, ¹³C NMR, HR-ESI-MS, and ATR-IR where appropriate (Figures S1–13). Particularly interesting, however, were the ¹H NMR spectra of the metalated H₄octapa ligand. Variable-temperature NMR experiments with In³⁺ complexes of DOTA have demonstrated fluxional isomerization in solution, despite the macrocyclic nature of the chelator.^{19,33,44} In this case, however, the ¹H NMR spectra obtained for [In(octapa)][−] and [Lu(octapa)][−] (**6**) reveal sharp and distinct coupling patterns, indicating little fluxional isomerization in solution at ambient temperature (Figure S5).³³




Figure 1. *In silico* DFT structure predictions of (a) 8-coordinate structure of $[\text{Lu}(\text{octapa})]^-$ and (b), 9-coordinate structure of $[\text{Lu}(\text{octapa})(\text{H}_2\text{O})]^-$ as well as the MEP polar-surface area maps (bottom) predicting the charge distribution over the solvent-exposed surface of the metal complexes (red = negative, blue = positive, representing a maximum potential of 0.254 au and a minimum of -0.254 au, mapped onto electron density isosurfaces of $0.002 \text{ \AA}^{-3}$), demonstrating very little difference between the 8- and 9-coordinate solution structures in terms of both geometry and charge distribution, suggesting little change in physical properties between the 8- and 9-coordinate geometries.

Thermodynamic Stability and Density Functional Theory Structure Prediction. The thermodynamic stability constants ($\log K_{\text{ML}}$) for DOTA with Lu^{3+} have previously been determined by spectrophotometric methods (UV) to be 23.5 and ~ 25 ^{45,46} and by a competitive potentiometric titration with oxalate to be 29.2 ± 0.2 .⁴⁷ In these studies the only species for which $\log K_{\text{ML}}$ has been documented is for the ML species (no metal hydroxide), and titrations were not done in the presence of sodium, which is known to lower formation constants values (our titrations are done in 0.15 M sodium for physiologically relevant conditions).⁴⁸ These factors, combined with the inconsistencies in the reported $\log K_{\text{ML}}$ values and the methods used, prompted us to perform competitive potentiometric titration experiments of DOTA with EDTA and Lu^{3+} in order to provide a formation constant that was determined under identical experimental conditions to our own system. Using potentiometric titrations, we have experimentally determined the thermodynamic stability constant ($\log K_{\text{ML}}$) for Lu^{3+} with H_4octapa to be 20.08 ± 0.09 ($\text{pM} = 19.8$) and with DOTA to be 21.62 ± 0.10 ($\text{pM} = 17.1$). In addition, the $\log K_{\text{ML}}$ value for Lu^{3+} with DTPA has been reported in the literature to be 22.4, and we have calculated a pM value of 19.1.¹⁷ Although the presence of sodium in our experiments can be expected to lower the stability constant of DOTA with Lu^{3+} from previously reported values, and the different experimental methods used are expected to vary in their results, the low $\log K_{\text{ML}}$ value we have obtained could be inaccurate as a result of the slow complex formation kinetics of DOTA. During the potentiometric titrations we performed, up to 15 min was allowed for stabilization of the electrode reading between each addition of base, which may have been too brief for a proper equilibrium to be established with DOTA. Previous work has waited over 2 weeks for equilibrium to be reached in this system, which highlights the sluggish formation kinetics.⁴⁵ Because of this

uncertainty, our experimentally determined $\log K_{\text{ML}}$ value for DOTA with Lu^{3+} cannot be relied on solely or be considered to be more accurate than previously determined values, and therefore all reported formation constants must be considered. The thermodynamic stability constants of the In^{3+} complexes of H_4octapa , DOTA, and DTPA have been determined to be 26.6 ($\text{pM} = 26.5$), 23.9 ($\text{pM} = 18.8$), and 29.0 ($\text{pM} = 25.7$), respectively.³³ It is important to note that thermodynamic stability is generally regarded as an unreliable predictor of *in vivo* stability on its own,¹⁶ and the kinetic inertness of a radiometal-complex is a much more valuable factor. For example, the $[\text{In}(\text{DOTA})]^-$ complex is widely established as being significantly more stable than $[\text{In}(\text{DTPA})]^{2-}$ both *in vivo* and *in vitro*, yet the thermodynamic stability constant for In^{3+} with DTPA is ~ 5 orders of magnitude higher than with DOTA (29.0 and 23.9, respectively). In fact, pM values, which are calculated from $\log K_{\text{ML}}$ values while taking into account ligand pK_a 's and metal ion hydroxide formation under specific and physiologically relevant conditions, are generally considered more useful in predicting *in vivo* stability than $\log K_{\text{ML}}$ values. H_4octapa has been shown to have high pM values with both In^{3+} (26.5) and Lu^{3+} (19.8), further substantiating its promising properties with these metals and their radioactive isotopologues.

The coordination geometry of both the 8- and 9-coordinate $[\text{Lu}(\text{octapa})]^-$ and $[\text{Lu}(\text{octapa})(\text{H}_2\text{O})]^-$ complexes were estimated *in silico* using density functional theory (DFT) calculations, and MEP polar surface area maps were superimposed on the structure (Figure 1). Both Lu^{3+} complexes were found to be highly symmetrical and very similar to one another; indeed, that the addition of an H_2O ligand results in very little change in metal–ligand bond lengths and angles suggests that water binding bears little influence on the coordination of the ligand. Importantly, the $[\text{Lu}(\text{octapa})]^-$ and $[\text{Lu}(\text{octapa})-$

Table 1. Chemical and *in Vitro* Biological Characterization Data for ^{111}In -/ ^{177}Lu -octapa- and ^{111}In -/ ^{177}Lu -DOTA-Trastuzumab Radioimmunoconjugates

immunoconjugate	isotope	radiolabeling conditions and yield	chelates/ mAb ^a	specific activity (mCi/mg)	immunoreactive fraction (%) ^b	serum stability 120 h (%) ^c
H ₄ octapa-trastuzumab	^{111}In	15 min, 25 °C, 94%	3.0 ± 0.1	4.0 ± 0.3	99.9 ± 0.02	94.9 ± 0.6
	^{177}Lu	15 min, 25 °C, 95%	3.0 ± 0.1	3.5 ± 0.4	99.2 ± 0.8	92.4 ± 0.6
DOTA-trastuzumab	^{111}In	60 min, 37 °C, 50–85%	3.4 ± 0.1	2.0 ± 0.2	93.2 ± 0.5	91.1 ± 0.6
	^{177}Lu	60 min, 37 °C, 50–88%	3.4 ± 0.1	3.4 ± 0.3	95.2 ± 0.2	98.6 ± 0.6

^aIsotopic dilution assays, $n = 3$. ^bDetermined immediately prior to *in vivo* experimentation, $n = 6$. ^cCalculated for incubation in human serum at 37 °C for 120 h, $n = 3$.

(H₂O)][−] DFT structures shown here are quite similar to the DFT structure of the 8-coordinate [In(octapa)][−] complex.³³ Taken together, the high log K_{ML} and pM values, the absence of fluxional behavior in solution, and the structural similarity between the [Lu(octapa)][−] and [In(octapa)][−] complexes strongly suggest that these two complexes should exhibit similar behavior *in vitro* and *in vivo*. This is especially important when considering ^{111}In as a SPECT imaging surrogate isotope for ^{177}Lu -based radiotherapies.

Bioconjugation and *In Vitro* Characterization. Synthesis and characterization data aside, the true value of any radiometal chelator ultimately lies in its behavior *in vitro* and *in vivo*. As a result, the next step in our investigation was to assess the *in vitro* and *in vivo* performance of H₄octapa in a model system based on the HER2/*neu*-targeting antibody trastuzumab and HER2-expressing SKOV-3 ovarian cancer cells. In order to provide a basis for comparison, radioimmunoconjugates bearing the ubiquitous chelator DOTA were also constructed and employed in parallel in all *in vitro* and *in vivo* experiments.

To begin, purified trastuzumab was incubated under slightly basic conditions (pH 8.5–9.0) with 4 equivalents of *p*-SCN-Bn-H₄octapa or *p*-SCN-Bn-DOTA and purified via size exclusion chromatography (PD-10, GE Healthcare, U.K.). Subsequent radiometric isotopic dilution experiments indicated that these modifications yielded 3.03 ± 0.1 chelates per antibody in the case of *p*-SCN-Bn-H₄octapa and 3.40 ± 0.1 chelates per antibody in the case of *p*-SCN-Bn-DOTA. H₄octapa-trastuzumab was then radiolabeled with either ^{111}In or ^{177}Lu in NH₄OAc buffer (pH 5.5, 200 mM) for 15 min at RT, rapidly producing quantitatively labeled radioimmunoconjugates (>95% radiochemical yield) in high radiochemical purity (>99% in each case) and specific activity (4.0 ± 0.3 and 3.5 ± 0.4 mCi/mg, respectively) (Figures S14–15). It is important to note that these labile kinetics offer a significant improvement over DOTA-trastuzumab, which required the less favorable incubation conditions of 1 h at 37 °C to achieve highly variable radiochemical yields of ~50–88% and to produce ^{111}In - and ^{177}Lu -labeled radioimmunoconjugates with specific activities of 2.0 ± 0.2 and 3.4 ± 0.3 mCi/mg, respectively (Table 1). These results are of practical significance because antibodies and radiometals are very expensive, and so the inconsistent yields provided when radiolabeling DOTA-trastuzumab could waste as much as 50% of the antibody construct and radiometal, greatly increasing cost and making translation to a clinical radiopharmacy setting more challenging.

The mild radiolabeling conditions afforded by H₄octapa-trastuzumab likely contributed to the extremely high immunoreactivity of the immunoconjugates as determined by *in vitro* cellular assays using SKOV-3 cancer cells: $99.9 \pm 0.02\%$ for ^{111}In -octapa-trastuzumab and $98.7 \pm 0.8\%$ for ^{177}Lu -octapa-trastuzumab. These values compared favorably to the slightly

lower but statistically different values determined for ^{111}In - and ^{177}Lu -DOTA-trastuzumab: $93.2 \pm 0.5\%$ and $95.2 \pm 0.2\%$, respectively (p -values of 0.003 and 0.02, respectively) (Table 1). In order to assay the stability of the radioimmunoconjugates under biological conditions, all four constructs were incubated in human serum at 37 °C for a period of 5 days. Over the course of the experiment, the stability of the ^{111}In -octapa- and ^{111}In -DOTA-trastuzumab was determined to be $94.9 \pm 0.6\%$ and $91.1 \pm 0.6\%$, respectively, and that of the ^{177}Lu -octapa- and ^{177}Lu -DOTA-based conjugates was found to be $92.4 \pm 0.6\%$ and $98.6 \pm 0.6\%$, respectively (Table 1). In the future, acid dissociation experiments and studies probing the ability of H₄octapa to radiolabel with ^{111}In and ^{177}Lu in the presence of an excess of metal ions, such as Ca²⁺, Mg²⁺, Cu²⁺, Zn²⁺, and Fe³⁺, are of interest.^{49,50}

Acute Biodistribution Studies. Biodistribution experiments were performed in order to directly compare the *in vivo* behavior and pharmacokinetics of the ^{111}In - and ^{177}Lu -based trastuzumab radioimmunoconjugates. To this end, each of the four radiolabeled antibodies: ^{111}In -octapa-trastuzumab, ^{177}Lu -octapa-trastuzumab, ^{111}In -DOTA-trastuzumab, and ^{177}Lu -DOTA-trastuzumab, were injected via tail vein into female nude athymic mice bearing subcutaneous SKOV-3 ovarian cancer xenografts in the right shoulder (~30 μCi , ~8–15 μg , in 200 μL of sterile saline; tumor volume ~100–150 mm³). After 24, 48, 72, 96, or 120 h ($n = 4$ per time point) the mice were euthanized via CO₂ (g) asphyxiation, and 13 organs, including the SKOV-3 tumors, were removed, weighed, and assayed for radioactivity on a γ -counter.

In all four cases, the biodistribution results showed all the hallmarks of tumor-targeted radioimmunoconjugates, specifically high levels of uptake in the blood pool at early time points giving way over time to increasing levels of uptake in the tumor and, ultimately, very high tumor-to-background organ activity ratios. In all four cases, the level of uptake in nontarget organs is roughly similar, with the highest levels of background uptake in the liver, spleen, and kidneys (Tables S1–3). However, past 24 h, the amount of activity in nontarget organs rarely exceeds 5–10 %ID/g; for example, at 96 h postinjection, ^{177}Lu -octapa-trastuzumab displays uptakes of 9.8 ± 1.7 %ID/g, 9.2 ± 1.1 %ID/g, and 3.8 ± 1.8 %ID/g in the liver, spleen, and kidneys, respectively. A close inspection of Table 2 reveals not only slightly higher uptake of ^{111}In - and ^{177}Lu -octapa-trastuzumab in the bone when compared to the DOTA-trastuzumab conjugates but also slightly lower uptake of ^{111}In - and ^{177}Lu -octapa-trastuzumab in the kidneys.

Far more interesting are the levels of tumor uptake, which are markedly higher with the ^{111}In -octapa- and ^{177}Lu -octapa-based variants compared to their ^{111}In -DOTA- and ^{177}Lu -DOTA-based analogs. For example, at 96 h postinjection the tumor uptake for ^{111}In -octapa- and ^{177}Lu -octapa-trastuzumab

Table 2. Biodistribution Data of ^{111}In -/ ^{177}Lu -octapa- and ^{111}In -/ ^{177}Lu -DOTA-Trastuzumab^a

^{111}In -octapa-trastuzumab						^{111}In -DOTA-trastuzumab					
organ	24 h	48 h	72 h	96 h	120 h	organ	24 h	48 h	72 h	96 h	120 h
blood	6.9 ± 5.1	7.6 ± 6.5	10.5 ± 7.1	6.9 ± 6.6	11.4 ± 6	blood	18 ± 1.7	17.3 ± 2.6	16.8 ± 2.2	15 ± 3.6	14.3 ± 1.6
tumor	57.4 ± 22	58.3 ± 17.2	57.8 ± 14.6	68.7 ± 20.5	72.4 ± 21.3	tumor	22.3 ± 6.4	28.4 ± 5.2	30.6 ± 9.1	32.8 ± 7.3	31.5 ± 3.8
heart	2.6 ± 0.5	2.5 ± 1.5	2.7 ± 1.4	1.9 ± 1.4	3.6 ± 1.6	heart	6.1 ± 0.9	6.6 ± 2	5.6 ± 1.3	5.2 ± 1.8	5.2 ± 0.9
lungs	4.4 ± 2.1	3.9 ± 2.3	5 ± 2.8	3.8 ± 3.3	6.3 ± 3	lungs	7.2 ± 1.6	6.8 ± 3.3	5.2 ± 1.4	6.3 ± 1.2	5.7 ± 2.2
liver	12 ± 2.4	10.6 ± 1.2	9.1 ± 0.8	8.5 ± 2	6.6 ± 0.6	liver	6.2 ± 0.4	5.5 ± 1.4	4.8 ± 1.3	4.4 ± 1.7	5.2 ± 1.2
spleen	8.9 ± 2.4	7.6 ± 1	8.1 ± 0.8	7.4 ± 1.1	6.5 ± 1.6	spleen	3.6 ± 0.8	3.7 ± 1.6	3 ± 0.7	2.7 ± 0.7	3.4 ± 1.4
stomach	1.4 ± 0.2	0.8 ± 0.2	1.2 ± 0.1	0.7 ± 0.3	0.7 ± 0.2	stomach	0.7 ± 0.1	0.7 ± 0.4	0.8 ± 0.2	0.3 ± 0.2	0.6 ± 0.3
lg intestine	3.7 ± 0.4	2.5 ± 0.7	2 ± 0.9	1.7 ± 0.4	1.2 ± 0.1	lg intestine	0.5 ± 0.1	0.6 ± 0.1	0.7 ± 0.1	0.5 ± 0.1	0.5 ± 0.1
sm intestine	3.8 ± 0.7	2.1 ± 0.4	2.5 ± 0.6	2.1 ± 0.4	1.5 ± 0.1	sm intestine	1.9 ± 0.1	1.6 ± 0.5	1.7 ± 0.1	1.1 ± 0.2	1.3 ± 0.1
kidney	3.6 ± 1.2	4.2 ± 2.1	4.3 ± 2.1	3.5 ± 2	4.3 ± 1.6	kidney	5.3 ± 0.5	6.3 ± 0.9	5.1 ± 1.7	5.8 ± 1.7	4.9 ± 0.4
muscle	1.3 ± 0.5	0.9 ± 0.5	1 ± 0.5	0.8 ± 0.5	0.9 ± 0.5	muscle	0.7 ± 0.2	0.8 ± 0.3	0.5 ± 0.1	0.4 ± 0.1	0.3 ± 0.1
bone	4.1 ± 2	3.5 ± 0.4	2.8 ± 1	3.3 ± 0.5	1.4 ± 0.3	bone	1 ± 0.3	0.9 ± 0.1	1.1 ± 0.4	0.9 ± 0.4	0.6 ± 0.2
skin	10.8 ± 1.4	9.3 ± 1.4	7.2 ± 2.1	5.4 ± 1.2	3 ± 1.1	skin	1.8 ± 0.4	2.1 ± 0.7	2.6 ± 0.1	1.7 ± 0.8	2.2 ± 0.8
^{177}Lu -octapa-trastuzumab						^{177}Lu -DOTA-trastuzumab					
organ	24 h	48 h	72 h	96 h	120 h	organ	24 h	48 h	72 h	96 h	120 h
blood	19.1 ± 1.5	9.1 ± 9.5	9.7 ± 5.2	8.9 ± 6.9	7.6 ± 5.7	blood	20.4 ± 1.7	17.4 ± 1	18.1 ± 2.8	15 ± 0.8	14.7 ± 0.7
tumor	50 ± 5.4	63.5 ± 15	62.4 ± 20	70.4 ± 25.8	56.6 ± 12.7	tumor	18.3 ± 4.8	31.6 ± 2.9	32.1 ± 7.4	37 ± 9.5	37.4 ± 10.3
heart	4.2 ± 0.7	3.2 ± 1.9	2.5 ± 0.9	2.3 ± 0.7	2.6 ± 1.4	heart	7.2 ± 1	4.9 ± 3.3	5.8 ± 1.6	4.6 ± 1.1	5.4 ± 0.6
lung	7.8 ± 3.6	3.9 ± 3.1	5 ± 2.3	4.4 ± 2.5	2.7 ± 1.8	lungs	10 ± 1.5	6.7 ± 4.6	7.1 ± 2.3	6.3 ± 0.6	6 ± 2.1
liver	10.1 ± 1.3	13.2 ± 4	9.5 ± 3.5	9.8 ± 1.7	8 ± 2.6	liver	4.5 ± 2	5.7 ± 3.6	5.7 ± 2.5	2.8 ± 0.9	3.7 ± 1.9
spleen	8.8 ± 2.3	11.5 ± 2.5	7.4 ± 2.8	9.2 ± 1.2	6.7 ± 2.4	spleen	3.8 ± 0.5	3.1 ± 2.9	3.2 ± 1	3.5 ± 0.4	3.8 ± 1
stomach	1.4 ± 0.3	1 ± 0.5	0.9 ± 0.4	1.1 ± 0.3	0.6 ± 0.2	stomach	0.7 ± 0.2	1.3 ± 1.9	0.9 ± 0.2	0.8 ± 0.2	0.7 ± 0.2
lg intestine	1.3 ± 0.3	1 ± 0.3	1.1 ± 0.5	1.1 ± 0.2	0.8 ± 0.2	lg intestine	0.6 ± 0.1	0.5 ± 0.3	0.8 ± 0.2	0.5 ± 0.1	0.6 ± 0.2
sm intestine	1.9 ± 0.5	2.5 ± 1.1	2 ± 0.9	2.3 ± 0.4	1.6 ± 0.4	sm intestine	1.7 ± 0.2	1.5 ± 1	1.5 ± 0.4	1.4 ± 0.3	1.2 ± 0.1
kidney	4.9 ± 0.9	3.8 ± 2	3.7 ± 1.2	3.8 ± 1.8	2.8 ± 1.2	kidney	5.5 ± 1.7	7.3 ± 0.7	5.1 ± 0.8	4.4 ± 0.2	7.1 ± 5
muscle	0.9 ± 0.2	0.7 ± 0.5	0.8 ± 0.5	0.5 ± 0.2	0.4 ± 0.2	muscle	0.7 ± 0.2	0.5 ± 0.4	0.4 ± 0.1	0.5 ± 0.2	0.5 ± 0.1
bone	3.2 ± 0.5	4 ± 0.6	3.1 ± 0.7	4.2 ± 1.5	3.6 ± 1.7	bone	1.2 ± 0	1.3 ± 0.8	1.3 ± 0.3	0.9 ± 0.2	1.4 ± 0.3
skin	8.4 ± 2	6.8 ± 2.9	6.9 ± 0.5	5.6 ± 1.2	4.1 ± 2.2	skin	1.9 ± 0.9	2.4 ± 1.7	2.1 ± 0.2	2.1 ± 0.7	3.1 ± 1.3

^aPerformed over a 5 day period in mice bearing SKOV-3 ovarian cancer xenografts, tumor volume ~100-150 mm³ (*n* = 4 for each time point), showing %ID/g values.




Figure 2. SPECT/CT imaging of the $^{111}\text{In}/^{177}\text{Lu}$ -octapa- and $^{111}\text{In}/^{177}\text{Lu}$ -DOTA-trastuzumab immunoconjugates. Imaging studies in female nude athymic mice with subcutaneous SKOV-3 xenografts (identified by arrow at right shoulder, tumor volume $\sim 100\text{--}150\text{ mm}^3$), showing transverse (top) and coronal (bottom) planar images bisecting the tumor, imaged at 24, 48, 72, 96, and 120 h post injection, see Figures S17–20 for 48 and 96 h time points.

was found to be $68.7 \pm 20.5\text{ \%ID/g}$ and $70.4 \pm 25.8\text{ \%ID/g}$, respectively, compared to $32.8 \pm 7.3\text{ \%ID/g}$ and $37.0 \pm 9.5\text{ \%ID/g}$ for the ^{111}In -DOTA- and ^{177}Lu -DOTA-trastuzumab constructs. Notably, despite the large range in errors, the p -values for these differences are 0.04 for the ^{111}In data sets and 0.05 for ^{177}Lu data sets, indicating statistically significant differences (two-tailed students t test, Tables S1–3). Statistical analysis of tumor uptake by one-way ANOVA provided p -values of 0.02 for the ^{111}In data sets and 0.05 for ^{177}Lu data sets. In imaging, tumor-to-tissue activity ratios are arguably even more important measures than absolute uptake values, as these ratios provide quantitative information regarding the contrast that will be observed during imaging. As a result of the excellent tumor uptake of the H_4octapa -based radioimmunoconjugates, the tumor-to-background activity ratios were higher than the corresponding DOTA-based agents for almost all organs. For example, the tumor-to-blood ratios for ^{111}In -octapa- and ^{111}In -DOTA-trastuzumab at 120 h were found to be 6.4 ± 3.8 and 2.2 ± 0.4 , respectively, while for ^{177}Lu -octapa- and ^{177}Lu -DOTA-trastuzumab they were 7.5 ± 5.8 and 2.5 ± 0.7 , respectively (Table S1).

The origin of the elevated tumor uptake values observed for the H_4octapa -trastuzumab agents could lie in the enhanced immunoreactivity conferred by the fast and mild radiolabeling conditions. However, the difference in immunoreactivity was only about 5%, a discrepancy that would not be expected to

cause such a change *in vivo*. Alternatively, it could be postulated that while the antigen-binding region of the antibody was only slightly adversely affected by temperature in the DOTA-trastuzumab conjugate, a separate region of the immunoglobulin may have suffered bond cleavage or protein structure disruption during radiolabeling, which in turn affected tumor uptake and retention. Finally, the differences in pharmacokinetic properties from attaching three to four relatively small chelating moieties to a 150 kD antibody are almost certainly insignificant, but it is not inconceivable that this modification could somehow affect the distribution of the radioimmunoconjugates *in vivo*. Experiments are currently underway to probe the origin of this elevated tumor uptake. Ultimately, regardless of the causation, the superior tumor uptake and tumor-to-tissue activity ratios plainly show that ^{111}In -octapa- and ^{177}Lu -octapa-trastuzumabs are highly effective and versatile radioimmunoconjugates and, more generally, that H_4octapa is a very promising ligand for the construction of biomolecular radiopharmaceuticals.

Small Animal SPECT/CT and Cerenkov Luminescence Imaging. Single photon emission computed tomography (SPECT) was used in conjunction with standard helical X-ray CT for *in vivo* imaging of all ^{111}In - and ^{177}Lu -labeled immunoconjugates over 5 days, visually demonstrating high uptake and clear delineation of the SKOV-3 ovarian cancer xenografts by ^{111}In - and ^{177}Lu -octapa-trastuzumab as well as

^{111}In - and ^{177}Lu -DOTA-trastuzumab (Figure 2). Images taken at early time points show residual activity in the blood pool at 24 h; however, at later time points, the background activity in the blood clears and is accompanied by a concomitant increase in the amount of activity in the tumor, culminating at a point at which the tumor is by far the most prominent feature in the image (Figures 2, S17–20). Overall, the image quality, tumor uptake, and contrast observed are very similar between the H_4octa - and DOTA-based constructs. In all four cases, high levels of tumor uptake and excellent tumor-to-background contrast are observed at later time points, data which correlate well with the high tumor uptake and tumor-to-tissue ratios revealed in the biodistribution experiments (Tables 2, S1–3). It is important to note that while the ^{111}In - and ^{177}Lu -octapa-trastuzumab images do not appear qualitatively superior to those produced by the ^{111}In -DOTA- and ^{177}Lu -DOTA variants, the enhanced tumor-to-background activity ratios of the ^{111}In - and ^{177}Lu -octapa-based constructs could potentially be of value in identifying small lesions or metastases in which absolute uptake of radioactivity is limited and for which contrast is crucial. The use of Cerenkov radiation (CR) for Cerenkov luminescence imaging (CLI) has been emerging as a new imaging modality, with applications such as intraoperative radionuclide-guided surgery for the resection of cancers.⁵¹ In order to probe the potential of our ^{177}Lu -labeled immunoconjugate, we have successfully imaged ^{177}Lu -octapa-trastuzumab via external optical imaging through the skin 24 h post injection via CLI (Figure 3). To our knowledge, we report the first published example of *in vivo* CLI imaging of ^{177}Lu (Figure 3).

CONCLUSIONS

Ultimately, the major benefit of the acyclic H_4octa chelator system over macrocyclic chelators, such as DOTA, lies in the ability to radiolabel with rapid kinetics at RT, a trait which has the potential to shorten radiolabeling times (<15 min),

streamline radiopharmaceutical production, and aid in the retention of antibody integrity and immunoreactivity during radiolabeling. Trastuzumab is a robust antibody and can generally withstand the radiolabeling conditions required by DOTA, and so although H_4octa provides significant and tangible benefits over DOTA as outlined in this manuscript, its use is not strictly required; however, when working with antibodies that are more sensitive than trastuzumab and are less forgiving of elevated temperatures and extended reaction times, a chelator with more facile reaction kinetics like *p*-SCN-Bn- H_4octa may become crucial. The high and reproducible radiochemical yields that H_4octa provides (>95%) are additionally important because antibodies are the most expensive component of these radiolabeled immunoconjugate systems by a large margin. The inconsistent yields obtained with DOTA (50–90%) can waste as much as 50% of these expensive compounds and radiometals and could make it difficult to reliably produce specific doses in a clinical radiopharmacy setting. Yet the advantages provided by H_4octa do not end with facile radiolabeling protocols. Potentiometric titrations, spectroscopic measurements, and prolonged serum stability assays indicate that this broadly versatile chelator forms highly thermodynamically stable and kinetically inert coordination complexes with isotopes of both Lu^{3+} and In^{3+} . Finally, and most importantly, acute biodistribution studies have shown that ^{111}In - and ^{177}Lu -octapa-trastuzumab specifically and selectively accumulate in SKOV-3 ovarian cancer xenografts *in vivo* to a degree unmatched by analogous ^{111}In - and ^{177}Lu -DOTA-trastuzumab radioimmunoconjugates. Further, SPECT/CT imaging reveals that both ^{111}In - and ^{177}Lu -octapa-trastuzumab are capable of delineating HER2-positive tumors *in vivo* with excellent contrast and high tumor-to-background activity ratios, producing images that are comparable to those created using ^{111}In - and ^{177}Lu -DOTA-trastuzumab. Taken together, these data clearly indicate that *p*-SCN-Bn- H_4octa is a versatile and exceedingly promising bifunctional chelator for the construction of highly potent and effective ^{111}In - and ^{177}Lu -labeled radiopharmaceuticals.

EXPERIMENTAL SECTION

Materials and Methods. All solvents and reagents were purchased from commercial suppliers (Sigma Aldrich, St. Louis, MO; TCI America, Portland, OR; Fisher Scientific, Waltham, MA) and were used as received unless otherwise indicated. DMSO used for chelator stock solutions was of molecular biology grade (>99.9%: Sigma, D8418). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid *para*-benzylisothiocyanate (*p*-SCN-Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX). Methyl-6-bromomethylpicolinate was synthesized according to a literature protocol.³³ Water used was ultrapure ($18.2\text{ M}\Omega\text{ cm}^{-1}$ at $25\text{ }^\circ\text{C}$, Milli-Q, Millipore, Billerica, MA). The analytical thin-layer chromatography (TLC) plates were aluminum-backed ultrapure silica gel (Siliaplate, 60 Å pore size, 250 μM plate thickness, Silicycle, Quebec, QC). Flash column silica gel was provided by Silicycle (Siliaflash Irregular Silica Gels F60, 60 Å pore size, 40–63 μm particle size, Silicycle, Quebec, QC). Automated column chromatography was performed using a Teledyne Isco (Lincoln, NE) CombiFlash R_f automated system with solid load cartridges packed with flash column silica gel and RediSep R_f gold reusable normal-phase silica columns and neutral alumina columns (Teledyne Isco, Lincoln, NE). ^1H and ^{13}C NMR spectra were recorded on Bruker AV300, AV400, or AV600 instruments; all spectra were




Figure 3. Cerenkov luminescence image of ^{177}Lu -octapa-trastuzumab. CLI obtained 24 h postinjection of a female nude athymic mouse bearing an SKOV-3 ovarian cancer xenograft on the right shoulder, indicated by white arrow (2 min acquisition time). The bright spots on the head of the mouse are the result of fluorescent molecules in the mouse food.

internally referenced to residual solvent peaks except for ^{13}C NMR spectra in D_2O , which were externally referenced to a sample of $\text{CH}_3\text{OH}/\text{D}_2\text{O}$. Low-resolution mass spectrometry was performed using a Waters liquid chromatography mass spectrometer (LC-MS) consisting of a Waters ZQ quadrupole spectrometer equipped with an ESI electrospray/chemical ionization ion source and a Waters 2695 HPLC system (Waters, Milford, MA). High-resolution electrospray-ionization mass spectrometry (ESI-MS) was performed on a Waters Micromass LCT time-of-flight instrument. Microanalyses for C, H, and N were performed on a Carlo Erba EA 1108 elemental analyzer. The HPLC system used for purification of non-radioactive compounds consisted of a semipreparative reverse phase C18 Phenomenex synergi hydro-RP (80 Å pore size, 250×21.2 mm, Phenomenex, Torrance, CA) column connected to a Waters 600 controller, a Waters 2487 dual wavelength absorbance detector, and a Waters delta 600 pump. ^{177}Lu (chelate) analysis was performed using an HPLC system comprised of a Shimadzu SPD-20A prominence UV-vis, LC-20AB prominence LC, a Bioscan flow-count radiation detector, and a C18 reverse phase column (Phenomenex Luna Analytical 250×4.6 mm). UV-vis measurements for determining antibody stock solution concentrations were taken on a Thermo Scientific Nanodrop 2000 spectrophotometer (Wilmington, DE).

^{111}In was cyclotron produced (Advanced Cyclotron Systems, Model TR30) by proton bombardment through the reactions $^{111}\text{Cd}(\text{p},\text{n})^{111}\text{In}$ and was provided by Nordion as $^{111}\text{InCl}_3$ in 0.05 M HCl. ^{177}Lu was procured from Perkin-Elmer (Perkin-Elmer Life and Analytical Sciences, Wellesley, MA, effective specific activity of 29.27 Ci/mg) as $^{177}\text{LuCl}_3$ in 0.05 M HCl. Labeling reactions were monitored using silica-gel impregnated glass-microfiber instant thin layer chromatography paper (iTLC-SG, Varian, Lake Forest, CA) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan Radio-TLC software (Bioscan Inc., Washington, DC). All radio-labeling chemistry was performed with ultrapure water (>18.2 MΩ cm^{-1} at 25 °C, Milli-Q, Millipore, Billerica, MA) that had been passed through a 10 cm column of Chelex resin (BioRad Laboratories, Hercules, CA). Human blood serum (Sigma, Sera, human, aseptically filled, S7023–100 mL) competition solutions were agitated at 550 rpm and held at 37 °C using an Eppendorf Thermomixer, and then ^{177}Lu (chelate) mixtures were analyzed using GE Healthcare Life Sciences PD-10 desalting columns (GE Healthcare, United Kingdom, MW < 5000 Da filter) that were conditioned by elution of 25 mL phosphate-buffered saline (PBS) before use. $^{177}\text{Lu}/^{111}\text{In}$ -immunoconjugates were analyzed using iTLC as described above and purified using PD-10 desalting columns and Corning 50k MW Amicon Ultra centrifugation filters. Radioactivity in samples was measured using a Capintec CRC-15R dose calibrator (Capintec, Ramsey, NJ), and for biodistribution studies a Perkin-Elmer (Waltham, MA) Automated Wizard Gamma Counter was used for counting organ activities and creating calibration curves. SPECT/CT imaging was performed using a four-headed NanoSPECT/CTPLUS camera (Bioscan Inc., Washington, DC, USA) with a multipinhole focused collimator and a temperature-controlled animal bed (Minerve equipment veterinaire). Imaging of CR was performed using a IVIS 200 (Caliper Life Sciences) optical imager. Human breast cancer cell line SKOV-3 was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and was grown by

serial passage. All animals used were female nude athymic mice (Taconic Farms, Inc., Hudson, NY).

N,N'-(2-Nitrobenzenesulfonamide)-1,2-diaminoethane (1). Ethylenediamine (548 μL , 8.2 mmol) was dissolved in THF (10 mL) and placed in an ice bath, then sodium bicarbonate (~2 g) was added, followed by slow addition of 2-nitrobenzenesulfonyl chloride (4.00 g, 18.1 mmol). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The yellow mixture was filtered to remove sodium bicarbonate, rotovapped to red oil, and then dissolved in a minimum volume of dichloromethane and placed in the freezer overnight. Product precipitated quickly and was filtered and then washed with cold dichloromethane (3×10 mL), and this process was repeated with the filtrate once more to recover more material. The faint yellow powder (1) was dried *in vacuo* for a yield of 87% (~3.07 g). ^1H NMR (300 MHz, $\text{DMSO}-d_6$, 25 °C) δ : 8.16 (br s, 2H), 8.00–7.94 (m, 4H), 7.90–7.83 (m, 4H), 3.00 (s, 4H). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$, 25 °C) δ : 147.62, 134.18, 132.76, 132.41, 129.45, 124.54, 42.39. HR-ESI-MS calcd for $[\text{C}_{14}\text{H}_{14}\text{N}_4\text{O}_8\text{S}_2 + \text{Na}]^+$: 453.0151; found: 453.0154 $[\text{M} + \text{Na}]^+$, PPM = 0.7.

N,N'-(2-Nitrobenzenesulfonamide)-*N,N'*-[6-(methoxycarbonyl)pyridin-2-yl]methyl]-1,2-diaminoethane (2). To a solution of 1 (1.17 g, 2.72 mmol) in dimethylformamide (10 mL, dried over molecular sieves 4 Å) was added methyl-6-bromomethyl picolinate³³ (1.38 g, 5.98 mmol) and sodium carbonate (~2 g). The faint yellow reaction mixture was stirred at 50 °C overnight, filtered to remove sodium carbonate, and concentrated *in vacuo*. The crude product was purified by silica chromatography (CombiFlash R_f automated column system; 40 g HP silica; A: dichloromethane, B: methanol, 100% A to 20% B gradient) to yield the product 2 as white fluffy solid (95%, ~1.88 g) (R_f : 0.9, TLC in dichloromethane). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ : 8.10–8.08 (m, 2H), 7.93 (dd, J = 7.8, 0.9 Hz, 2H), 7.75 (t, J = 7.8 Hz, 2H), 7.66–7.62 (m, 4H), 7.60–7.57 (m, 2H), 7.51 (dd, J = 7.8, 0.9 Hz, 2H), 4.71 (s, 4H), 3.91 (s, 6H), 3.51 (s, 4H). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ : 165.07, 156.21, 147.83, 147.41, 137.89, 133.65, 132.34, 131.93, 131.22, 125.64, 124.09, 124.04, 53.52, 52.65, 46.69. HR-ESI-MS calcd for $[\text{C}_{30}\text{H}_{28}\text{N}_6\text{O}_{12}\text{S}_2 + \text{H}]^+$: 729.1285; found: 729.1263, $[\text{M} + \text{H}]^+$, PPM = –3.0.

N,N'-[6-(Methoxycarbonyl)pyridin-2-yl]methyl]-1,2-diaminoethane (3). To a solution of 2 (1.48 g, 2.03 mmol) in tetrahydrofuran (10 mL) was added thiophenol (457 μL , 4.47 mmol) and potassium carbonate (excess, ~1 g). The reaction mixture was stirred at ambient temperature for 72 h, where a slow color change from colorless to dark yellow occurred. The reaction mixture was split into two 20 mL falcon tubes, diluted with additional tetrahydrofuran, and centrifuged for 5 min at 4000 rpm, and then the solvent was decanted. The potassium carbonate in the falcon tubes was rinsed/centrifuged/decanted with tetrahydrofuran 3 times and pooled, and the organic fractions were concentrated to dryness *in vacuo*. Please note that the potassium carbonate can be very sticky (varies between supplier) and can clog gravity and vacuum filters, and so to prevent product loss the method of centrifugation is recommended if a sticky texture is observed after reaction. The resulting crude yellow oil was purified by silica chromatography (CombiFlash R_f automated column system; 24 g neutral alumina; A: dichloromethane, B: methanol, 100% A to 30% B gradient) to yield 3 as clear colorless oil (91%, ~0.66 g). Compound 3 was purified using neutral alumina, as it demonstrates an abnormally high affinity for silica and requires

the use of ammonium hydroxide and >20% methanol to be eluted, resulting in partial methyl-ester deprotection and dissolving of some silica. ^1H NMR (300 MHz, MeOD, 25 °C) δ : 8.02 (d, J = 7.5 Hz, 2H), 7.94 (t, J = 7.6 Hz, 2H), 7.66 (d, J = 7.5 Hz, 2H), 3.96 (s, 6H), 2.79 (s, 4H). ^{13}C NMR (75 MHz, MeOD, 25 °C) δ : 167.04, 161.45, 148.48, 139.51, 127.61, 124.84, 54.92, 53.37, 50.00, 49.27. HR-ESI-MS calcd for $[\text{C}_{18}\text{H}_{22}\text{N}_4\text{O}_4 + \text{H}]^+$: 359.1719; found: 359.1720, $[\text{M} + \text{H}]^+$, PPM = 0.2.

N,N'-[*(tert*-Butoxycarbonyl)methyl-*N,N'*-[6-(methoxycarbonyl)pyridin-2-yl]methyl]-1,2-diaminoethane (**4**). To a solution of **3** (212 mg, 0.593 mmol) in dry acetonitrile (10 mL, distilled over CaH_2) was added *tert*-butylbromoacetate (202 μL , 1.36 mmol) and sodium carbonate (~300 mg). The reaction was stirred at 60 °C overnight. Sodium carbonate was removed by filtration, and the crude reaction mixture was concentrated *in vacuo*. The crude oil was purified by column chromatography (CombiFlash R_f automated column system; 24 g HP silica; A: dichloromethane, B: methanol, 100% A to 20% B gradient) to afford the product **4** as light-yellow oil (92%, ~0.32 g). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ : 7.95 (dd, J = 7.2, 1.4 Hz, 2H), 7.80–7.70 (m, 4H), 3.97 (s, 4H), 3.95 (s, 6H), 3.28 (s, 4H), 2.78 (s, 4H), 1.40 (s, 18H). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ : 170.36, 165.77, 160.79, 147.09, 137.29, 126.02, 123.48, 80.91, 60.51, 56.27, 52.75, 52.39, 28.05. HR-ESI-MS calcd for $[\text{C}_{30}\text{H}_{42}\text{N}_4\text{O}_8 + \text{H}]^+$: 587.3081; found: 587.3085, $[\text{M} + \text{H}]^+$, PPM = 0.7.

*H*₄octapa, *N,N'*-(6-carboxy-2-pyridylmethyl)-*N,N'*-diacetic acid-1,2-diaminoethane (**5**). Compound **4** (138 mg, 0.235 mmol) was dissolved in HCl (10 mL, 6 M) and refluxed for 12 h at 140 °C. The reaction mixture was concentrated *in vacuo* and then purified via semiprep reverse-phase HPLC (10 mL/min, gradient: A: 0.1% TFA (trifluoroacetic acid) in deionized water, B: 0.1% TFA in CH_3CN . 0 to 70% B linear gradient 30 min. t_R = 12.6 min, broad). Product fractions were pooled, concentrated *in vacuo*, dissolved in 6 M HCl, and then concentrated *in vacuo* again to remove trifluoroacetic acid. The HCl salt *H*₄octapa-4HCl-2H₂O (**5**) was obtained as a white solid (66% yield, ~0.097 g, using the molecular weight of the HCl salt as determined by elemental analysis). ^1H NMR (300 MHz, D_2O) δ : 8.11–8.01 (m, 4H, pyr-H), 7.72–7.69 (m, 2H, pyr-H), 4.53 (s, 4H, Pyr-CH₂-N), 3.97 (s, 4H, HOOC-CH₂-N), 3.57 (s, 4H, ethylene-H). ^{13}C NMR (75 MHz, D_2O) δ : 170.33, 165.27, 151.19, 145.09, 142.64, 128.60, 126.12, 57.81, 54.97, 51.22. IR (neat, ATR-IR): ν = 1721 cm^{-1} (C=O), 1636/1618 cm^{-1} (C=C py). HR-ESI-MS calcd for $[\text{C}_{20}\text{H}_{22}\text{N}_4\text{O}_8 + \text{H}]^+$: 447.1515; found $[\text{M} + \text{H}]^+$: 447.1526, PPM = 0.7. Elemental analysis: calcd % for *H*₄octapa-4HCl-2H₂O ($\text{C}_{20}\text{H}_{22}\text{N}_4\text{O}_8 \cdot 4\text{HCl} \cdot 2\text{H}_2\text{O}$ = 628.2839): C 38.23, H 4.81, N 8.92; found: C 37.94, H 4.66, N 8.59.

[Na][Lu(octapa)] (**6**). Compound **5** (9.8 mg, 0.013 mmol) was suspended in 0.1 M HCl (1.5 mL) and $\text{LuCl}_3 \cdot 6\text{H}_2\text{O}$ (6.1 mg, 0.015 mmol) was added. The pH was adjusted to 4–5 using 0.1 M NaOH, and then the solution was stirred at RT. After 1 h the product was confirmed via mass spectrometry, and the solvent was removed *in vacuo* to yield [Lu(octapa)][Na] (**6**). ^1H NMR (600 MHz, D_2O , 25 °C) δ : 8.28–8.12 (m, 3H), 8.06 (d, J = 8.2 Hz, 2H), 7.81–7.67 (m, 2H), 4.56–4.48 (m, 1.5H), 4.33–4.05 (m, 2H), 3.81–3.74 (m, 1H), 3.51–3.43 (m, 2H) 3.26–3.16 (m, 4H), 3.00–2.98 (m, 0.5H), 2.57–2.55 (m, 0.5H), 2.12 (br s, 0.5H). ^{13}C NMR (150 MHz, D_2O , 25 °C) δ : 180.75, 177.07, 173.29, 172.78, 171.72, 158.17, 157.23, 155.65, 154.34, 150.65, 149.89, 149.55, 143.81, 142.96, 142.54, 141.42,

126.78, 126.43, 124.64, 124.50, 123.97, 65.71, 64.25, 62.27, 61.01, 60.51, 59.11, 57.63, 55.96. HR-ESI-MS calcd for $[\text{C}_{20}\text{H}_{18}^{175}\text{LuN}_4\text{O}_8 + 2\text{Na}]^+$: 663.0328; found: 663.0318, $[\text{M} + 2\text{Na}]^+$, PPM = –1.5.

1-(*p*-Nitrobenzyl)ethylenediamine (**7**). Compound **7** was prepared according to a literature preparation.⁵² Product was purified with a modified procedure using column chromatography (CombiFlash R_f automated column system; 40 g HP silica; A: 95% dichloromethane 5% ammonium hydroxide, B: 95% methanol 5% ammonium hydroxide, 100% A to 30% B gradient) to afford **7** as brown/amber oil in a cumulative yield of 40% over 3 steps (~3 g). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ : 7.91 (d, J = 8.9 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 2.80–2.57 (m, 3H), 2.45–2.31 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ : 147.13, 147.71, 129.39, 122.83, 54.26, 47.52, 41.36. HR-ESI-MS calcd. for $[\text{C}_9\text{H}_{13}\text{N}_3\text{O}_2 + \text{H}]^+$: 196.1086; found: 196.1084 $[\text{M} + \text{H}]$, PPM = –1.0.

N,N'-(2-Nitrobenzenesulfonamide)-1-(*p*-nitrobenzyl)-1,2-diaminoethane (**8**). Compound **7** (578 mg, 2.96 mmol) was dissolved in THF (10 mL) and placed in an ice bath, then sodium bicarbonate (~2 g) was added, followed by slow addition of 2-nitrobenzenesulfonyl chloride (1.58 g, 7.1 mmol). The reaction mixture was heated to 50 °C and stirred overnight. The yellow/orange mixture was filtered to remove sodium bicarbonate, rotovapped to orange oil, and then dissolved in a minimum volume of dichloromethane and placed in the freezer. Product precipitated quickly, filtered, and then washed with cold dichloromethane (3 $\times$ 10 mL), and this process was repeated with the filtrate twice more to recover more product. The faint yellow powder (**8**) was dried *in vacuo* for a yield of 74% (~1.24 g) (R_f : 0.90, TLC in 10% methanol in dichloromethane). ^1H NMR (300 MHz, acetone- d_6 , 25 °C) δ : 8.18–8.15 (m, 1H), 7.99–7.94 (m, 2H), 7.79–7.57 (m, 5H), 7.33 (d, J = 8.5 Hz, 2H), 7.04–6.98 (m, 2H), 4.01 (br s, 1H), 3.41–3.38 (m, 2H), 3.26 (dd, J = 3.4, 13.7 Hz, 1H), 2.98 (m, 1H). ^{13}C NMR (75 MHz, acetone- d_6 , 25 °C) δ : 206.33, 149.17, 148.14, 147.58, 146.74, 135.23, 134.79, 134.26, 133.89, 133.77, 133.57, 131.67, 131.38, 130.94, 126.00, 125.67, 123.90, 57.67, 49.35, 38.20. HR-ESI-MS calcd for $[\text{C}_{21}\text{H}_{19}\text{N}_5\text{O}_{10}\text{S}_2 + \text{Na}]^+$: 588.0471; found: 588.0465 $[\text{M} + \text{Na}]^+$, PPM = –1.0.

N,N'-(2-Nitrobenzenesulfonamide)-*N,N'*-[*(tert*-butoxycarbonyl)methyl]-1-(*p*-nitrobenzyl)-1,2-diaminoethane (**9**). To a solution of **8** (224 mg, 0.390 mmol) in dimethylformamide (5 mL, dried over molecular sieves 4 Å) was added *tert*-butylbromoacetate (169.7 mg, 0.87 mmol) and sodium carbonate (~400 mg). The yellow reaction mixture was stirred at 50 °C overnight, filtered to remove sodium carbonate, and concentrated *in vacuo*. The crude product was purified by silica chromatography (CombiFlash R_f automated column system; 40 g HP silica; A: ethyl acetate, B: petroleum ether, 100% A to 100% B gradient) to yield **9** as white fluffy solid (88%, ~0.27 g). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ : 7.98 (d, J = Hz, 2H), 7.84–7.39 (m, 8H), 7.25 (d, J = Hz, 2H), 4.46 (Br s, 1H), 4.33–3.85 (m, 6 H), 3.53 (m, 1H), 3.39 (m, 1H), 2.91 (m, 1H), 1.40 (s, 18H). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ : 168.35, 167.64, 148.00, 147.09, 146.31, 144.83, 133.91, 133.61, 132.53, 131.81, 131.72, 131.60, 131.51, 130.65, 129.85, 124.01, 123.01, 82.71, 82.53, 58.48, 52.47, 50.70, 45.37, 35.04, 27.69. HR-ESI-MS calcd. for $[\text{C}_{33}\text{H}_{39}\text{N}_5\text{O}_{14}\text{S}_2 + \text{Na}]^+$: 816.1833; found: 816.1838, $[\text{M} + \text{Na}]^+$, PPM = 0.6.

N,N'-[*(tert*-Butoxycarbonyl)methyl]-1-(*p*-nitrobenzyl)-1,2-diaminoethane (**10**). To a solution of **9** (151 mg, 0.189 mmol) in tetrahydrofuran (5 mL) was added thiophenol (41 μL , 0.398

mmol) and potassium carbonate. The reaction mixture was stirred at ambient temperature for 72 h, where a slow color change from colorless to dark yellow occurred. The reaction mixture was split into two 20 mL falcon tubes, diluted with additional tetrahydrofuran, centrifuged for 5 min at 4000 rpm, and then the solvent was decanted. The potassium carbonate in the falcon tubes was rinsed with tetrahydrofuran and centrifuged 3 times, pooled, and then concentrated to dryness *in vacuo*. The resulting crude yellow oil was purified by silica chromatography (CombiFlash R_f automated column system; 24 g HP silica; A: dichloromethane, B: methanol, 100% A to 20% B gradient) to yield **10** as clear colorless oil (89%, ~0.071 g). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ : 8.12 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 3.30 (s, 2H), 3.23–3.22 (m, 2H), 2.87–2.84 (m, 3H), 2.62 (m, 1H), 2.40 (m, 1H), 2.12 (Br s, 2H, -NH), 1.41 (s, 18H). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ : 171.68, 171.53, 147.07, 146.51, 130.07, 123.46, 81.17, 81.04, 58.28, 51.57, 49.34, 39.16, 28.01. HR-ESI-MS calcd. for $[\text{C}_{21}\text{H}_{33}\text{N}_3\text{O}_6 + \text{H}]^+$: 424.2448; found: 424.2451, $[\text{M} + \text{H}]^+$, PPM = 0.7.

N,N'-[(*tert*-Butoxycarbonyl)methyl]-*N,N'*-[(6-methoxycarbonyl)pyridin-2-yl)methyl]-1-(*p*-nitrobenzyl)-1,2-diaminoethane (**11**). To a solution of **10** (71.7 mg, 0.169 mmol) in dry acetonitrile (5 mL, distilled over CaH_2) was added methyl 6-(bromomethyl)picolinate³³ (85.7 mg, 0.372 mmol) and sodium carbonate (~200 mg). The reaction was stirred at 60 °C overnight. Sodium carbonate was removed by filtration, and the crude reaction mixture was concentrated *in vacuo*. The crude oil was purified by column chromatography (CombiFlash R_f automated column system; 24 g HP silica; A: dichloromethane, B: methanol, 100% A to 20% B gradient) to afford the product **11** as light-yellow oil (96%, ~0.117 g). ^1H NMR (300 MHz, MeOD, 25 °C) δ : 8.18 (d, J = 8.7 Hz, 2H), 8.11–8.02 (m, 3H), 7.95 (t, J = 7.8 Hz, 1H), 7.73–7.72 (m, 1H), 7.48–7.45 (m, 3H), 4.05 (s, 3H, methyl ester), 3.98 (s, 3H, methyl ester), 3.76 (m, 2H), 3.51 (d, J = 17.4 Hz, 1H), 3.38–3.31 (m, 2H), 3.25–3.20 (m, 2H), 3.16–3.01 (m, 2H), 2.89–2.82 (m, 2H), 2.71–2.64 (m, 1H), 2.55–2.51 (m, 1H), 1.39 (s, 18H). ^{13}C NMR (75 MHz, MeOD, 25 °C) δ : 174.44, 173.45, 167.07, 166.81, 160.17, 160.06, 149.25, 148.67, 148.51, 148.09, 140.34, 140.13, 131.60, 129.00, 128.57, 125.14, 125.04, 124.84, 83.39, 83.26, 63.82, 61.82, 58.41, 57.05, 53.78, 53.61, 34.10, 28.38. HR-ESI-MS calcd for $[\text{C}_{36}\text{H}_{48}\text{N}_5\text{O}_{10} + \text{H}]^+$: 722.3401; found: 722.3390, $[\text{M} + \text{H}]^+$, PPM = -1.5.

p-SCN-Bn- H_4octa pa, *N,N'*-[(Carboxylato)methyl]-*N,N'*-[(6-carboxylato)pyridin-2-yl)methyl]-1-(*p*-benzyl-isothiocyanato)-1,2-diaminoethane (**12**). Compound **11** (118 mg, 0.16 mmol) was dissolved in glacial acetic acid (2.5 mL) with hydrochloric acid (2.5 mL, 3 M), palladium on carbon (20 wt %), and hydrogen gas (balloon). The reaction was stirred vigorously at RT for 1 h, then filtered to remove Pd/C and washed *ad libitum* with methanol and hydrochloric acid (3 M). The crude reaction mixture was concentrated *in vacuo*, dissolved in 15 mL of hydrochloric acid (6 M), and refluxed overnight to facilitate deprotection of the methyl and *tert*-butyl esters. HR-ESI-MS calcd for $[\text{C}_{27}\text{H}_{29}\text{N}_5\text{O}_8 + \text{H}]^+$: 552.2094; found: 552.2098, $[\text{M} + \text{H}]^+$, PPM = 0.7. Without purification, the crude reaction mixture was dissolved in hydrochloric acid (1 mL, 3 M) and then reacted with thiophosgene (purchased suspended in chloroform) in ~0.2 mL of additional chloroform (15 equiv, 2.45 mmol) overnight at ambient temperature with vigorous stirring. The reaction mixture was washed with chloroform (5 $\times$ 1 mL) by vigorous biphasic stirring followed

by decanting of the organic phase with a pipet to remove excess thiophosgene, diluted to a volume of 4.5 mL with deionized water, and injected directly onto a semiprep HPLC column for purification (A: 0.1% TFA in deionized water, B: 0.1% TFA in CH_3CN , 100% A to 60% B gradient over 40 min). *p*-SCN-Bn- H_4octa pa (**12**) was found in the largest peak at R_t = 34 min (broad, Figure S22), lyophilized overnight, and isolated as a fluffy white solid (50% over 3 steps from **11**, ~0.047 g). ^1H NMR (400 MHz, MeOD, 25 °C) δ : 8.00–7.87 (m, 4H), 7.59–7.54 (m, 2H), 7.14 (dd, J = 7.7 Hz, 35.4 Hz, 4H), 5.03 (Br m, 1H), 4.66 (Br m, 2H), 4.49–4.45 (Br m, 1H), 4.11 (Br m, 1H), 3.92 (Br m, 2H), 3.66–3.59 (m, 2H), 3.35–3.18 (Br m, 3H), 2.66–2.60 (m, 1H). ^{13}C NMR (100 MHz, MeOD, 25 °C) δ : 173.10, 167.95, 166.02, 165.82, 161.34, 160.97, 159.40, 151.40, 147.74, 147.21, 138.63, 138.54, 137.60, 135.72, 130.30, 129.75, 127.51, 126.61, 125.65, 124.72, 123.94, 60.31, 59.74, 54.20, 54.14, 33.35. HR-ESI-MS calcd for $[\text{C}_{28}\text{H}_{27}\text{N}_5\text{O}_8\text{S} + \text{H}]^+$: 594.1659; found: 594.1661, $[\text{M} + \text{H}]^+$, PPM = 0.3.

Solution Thermodynamics. The experimental procedures and details of the apparatus closely followed those of a previous study for H_2dedpa with Ga^{3+} and H_4octa pa for In^{3+} .^{30,33} As a result of the strength of the binding of the Lu^{3+} complexes, $[\text{Lu}(\text{octa})]^-$ and $[\text{Lu}(\text{DOTA})]^-$, the complex formation constants with these ligands could not be determined directly, and the ligand–ligand competition method using the known competitor $\text{Na}_2\text{H}_2\text{EDTA}$ was used. Potentiometric titrations were performed using a Metrohm Titrando 809 equipped with a Ross combination pH electrode and a Metrohm Dosino 800. Data were collected in triplicate using PC Control (Version 6.0.91, Metrohm). The titration apparatus consisted of a water-jacketed glass vessel maintained at 25.0 (± 0.1 °C, Julabo water bath). Prior to and during the course of the titration, a blanket of nitrogen, passed through 10% NaOH to exclude any CO_2 , was maintained over the sample solution. Lutetium ion solutions were prepared by dilution of the appropriate atomic absorption standard (AAS) solution. The exact amount of acid present in the lutetium standard was determined by titration of an equimolar solution of Lu^{3+} and $\text{Na}_2\text{H}_2\text{EDTA}$. The amount of acid present was determined by Gran's method.⁵³ Calibration of the electrode was performed prior to each measurement by titrating a known amount of HCl with 0.1 M NaOH. Calibration data were analyzed by standard computer treatment provided within the program MacCalib⁵⁴ to obtain the calibration parameters E_0 . Equilibration times for titrations were 10 min pK_a titrations and 15 min for metal complex titrations. Ligand and metal concentrations were in the range of 0.75–1.0 mM for potentiometric titrations. The data were treated by the program Hyperquad2008.⁵⁵ The proton dissociation constant corresponding to hydrolysis of $\text{Lu}^{3+}(\text{aq})$ ion included in the calculations were taken from Baes and Mesmer.⁵⁶ The acid dissociation constants for DOTA and the K_{ML} value for the lutetium–EDTA complex were taken from Martell and Smith.¹⁷ pM values were calculated at physiologically relevant conditions of pH 7.4, 100 μM ligand, and 10 μM metal. All values and errors represent the average of at least three independent experiments.

Molecular Modeling. Calculations were performed using the Gaussian 09⁵⁷ and GaussView packages. Molecular geometries and electron densities were obtained from DFT calculations, with the B3LYP functional employing the 6-31+G(d,p) basis set for first- and second-row elements and the Stuttgart–Dresden effective core potential, SDD for lutetium.^{58–60} Solvent (water) effects were described through a continuum

approach by means of the IEF PCM as implemented in G09. The electrostatic potential was mapped onto the calculated electron density surface.

¹⁷⁷Lu(chelate) Radiolabeling. For ¹⁷⁷Lu experiments, the chelators H₄octapa, DTPA, and DOTA were used. Aliquots of each chelator stock solution (1 mg/mL) were transferred to Corning 2.0 mL self-standing microcentrifuge tubes containing ~1.2 mCi of ¹⁷⁷Lu to a ligand concentration of ~180 μM and made up to 1 mL with NaOAc buffer (10 mM, pH 5.0). H₄octapa and DTPA were allowed to radiolabel at ambient temperature for 10 min, and DOTA was radiolabeled for 1 h at 90 °C. Radiometal complexes were then evaluated using radio-HPLC (linear gradient A: 0.1% TFA in H₂O, B: CH₃CN, 0–80% B over 30 min): [¹⁷⁷Lu(octapa)][−] *t*_R = 5 min, >99%; [¹⁷⁷Lu(DOTA)][−] *t*_R = 6.8 min, >99%, [¹⁷⁷Lu(DTPA)]^{2−} *t*_R = 5.2 min, >99%. Radiolabeled chelators were then used for blood serum stability assays.

Trastuzumab Antibody Modification/Thiourea Bioconjugation. Trastuzumab (purchased commercially as Herceptin, Genentech, San Francisco, CA) was purified using centrifugal filter units with a 50 000 molecular weight cutoff (Amicon ultracentrifuge filters, Ultracel-50: regenerated cellulose, Millipore Corp., Billerica, MA) and phosphate buffered saline (PBS, pH 7.4) to remove α-α-trehalose dihydrate, L-histidine, and polysorbate 20 additives. After purification, the antibody was taken up in PBS pH 7.4. Subsequently, 300 μL of antibody solution (150–250 μM) was combined with 100 μL PBS (pH 8.0), the pH of the resulting solution was adjusted to 8.8–9.0 with 0.1 M Na₂CO₃, and 4 equiv of the *p*-SCN-Bn-H₄octapa or *p*-SCN-Bn-DOTA was added in 10 μL DMSO. The reactions were incubated at 37 °C for 1 h, followed by centrifugal filtration to purify the resultant antibody conjugate. The final modified antibody stock solutions were stored in PBS (pH 7.4) at 4 °C.

¹¹¹In- and ¹⁷⁷Lu-octapa/DOTA-Trastuzumab Radiolabeling. Aliquots of H₄octapa/DOTA-trastuzumab immunoconjugates were transferred to 2 mL microcentrifuge tubes and made up to 1 mL of ammonium acetate buffer (pH 5.5, 200 mM), and then aliquots of ¹⁷⁷Lu or ¹¹¹In were added (~2–3 mCi). The H₄octapa-trastuzumab mixtures were allowed to radiolabel at RT for 15 min and then analyzed via iTLC with an eluent of 50 mM EDTA (pH 5), and confirmed reproducible RCY values of >95% were obtained. The DOTA-trastuzumab mixtures were heated to 37 ± 0.1 °C for 1 h and then analyzed via iTLC, with RCYs ranging from ~50–90%. 30 μL of EDTA solution (50 mM, pH 5) was then added to the reaction mixture, and the resultant radiolabeled immunoconjugates were then purified using size-exclusion chromatography (Sephadex G-25 M, PD-10 column, 30 kDa, GE Healthcare; dead volume = 2.5 mL, eluted with 1 mL fractions of PBS, pH 7.4) and centrifugal column filtration (Amicon ultra 50k). The radiochemical purity of the final radiolabeled bioconjugate was assayed by radio-iTLC and was found to be >99% in all preparations. In the iTLC experiments, ¹¹¹In- and ¹⁷⁷Lu-octapa/DOTA-trastuzumab remained at the baseline, while ¹⁷⁷Lu³⁺/¹¹¹In³⁺ ions complexed as [¹¹¹In/¹⁷⁷Lu]-EDTA eluted with or near the solvent front.

Chelate Number Isotopic Dilution Assay. The number of accessible H₄octapa and DOTA chelates conjugated to trastuzumab was measured by radiometric isotopic dilution assays following methods similar to those described by Anderson et al. and Holland et al.^{9,61–63} All experiments were performed in triplicate.

In Vitro Immunoreactivity Assay. The immunoreactivity of the ¹¹¹In- and ¹⁷⁷Lu-octapa-trastuzumab and ¹¹¹In- and ¹⁷⁷Lu-DOTA-trastuzumab bioconjugates was determined using specific radioactive cellular-binding assays following procedures derived from Lindmo et al.^{64,65} To this end, SKOV-3 cells were suspended in microcentrifuge tubes at concentrations of 5.0, 4.0, 3.0, 2.5, 2.0, 1.5, and 1.0 × 10⁶ cells/mL in 500 μL PBS (pH 7.4). Aliquots of either ¹¹¹In- and ¹⁷⁷Lu-octapa-trastuzumab or ¹¹¹In- and ¹⁷⁷Lu-DOTA-trastuzumab (50 μL of a stock solution of 10 μCi in 10 mL of 1% bovine serum albumin in PBS pH 7.4) were added to each tube (*n* = 6; final volume: 550 μL), and the samples were incubated on a mixer for 60 min at RT. The treated cells were then pelleted via centrifugation (3000 rpm for 5 min), resuspended, and washed twice with cold PBS before removing the supernatant and counting the activity associated with the cell pellet. The activity data were background corrected and compared with the total number of counts in appropriate control samples. Immunoreactive fractions were determined by linear regression analysis of a plot of (total/bound) activity against (1/[normalized cell concentration]). No weighting was applied to the data, and data were obtained as *n* = 6.

¹⁷⁷Lu(chelate) Blood Serum Competition Experiments. Frozen human blood serum was thawed for 30 min, and 750 μL aliquots were transferred to 2.0 mL Corning centrifuge vials. 300 μL of each ¹⁷⁷Lu(chelator) was transferred to 750 μL of blood serum, along with 450 μL of PBS to a total volume of 1.5 mL (*n* = 3 for each chelator). The final ¹⁷⁷Lu(chelate) concentration present in serum was ~36 μM. Serum competition samples were then incubated at 37 ± 0.1 °C with constant agitation (550 rpm) and analyzed via PD-10 size-exclusion column elution (filters MW < 5000 Da) at 1.5 and 24 h time points and counted using a Capintec CRC-15R dose calibrator. 500 μL of each serum/¹⁷⁷Lu(chelator) competition solution (*n* = 3) was removed from the competition vial, diluted to 2.5 mL with PBS, and counted. The diluted aliquot of serum competition mixture was loaded onto a conditioned PD-10 column. The loading volume (2.5 mL) was eluted into radioactive waste, and then an additional 3.5 mL of PBS was loaded, collected, and counted in the dose calibrator as the serum-bound ¹⁷⁷Lu (nonchelate bound). Percent stability was reported as a percentage of ¹⁷⁷Lu still chelate-bound and not associated with serum proteins (MW < 5000 Da).

¹¹¹In- and ¹⁷⁷Lu-octapa/DOTA-Trastuzumab Blood Serum Competition Experiments. Frozen human blood serum was thawed for 30 min, and 300 μL aliquots were transferred to 2.0 mL Corning centrifuge vials. A portion of radiolabeled immunoconjugate (~300 μCi) was transferred to the blood serum (*n* = 3 for each chelator). Serum competition samples were then incubated at 37 ± 0.1 °C with gentle agitation (300 rpm) and analyzed via iTLC with an EDTA eluent (50 mM, pH 5.0) (Bioscan AR-2000) at time points of 0, 24, 48, 72, 96, and 120 h.

Cell Culture. Human ovarian cancer cell line SKOV-3 was obtained from the American Tissue Culture Collection (ATCC, Bethesda, MD) and maintained in a 1:1 mixture of Dulbecco's Modified Eagle medium: F-12 medium, supplemented with 10% heat-inactivated fetal calf serum (Omega Scientific, Tarzana, Ca), 2.0 mM glutamine, nonessential amino acids, 100 units/mL penicillin, and 100 units/mL streptomycin in a 37 °C environment containing 5% CO₂. Cell lines were harvested and passaged weekly using a formulation of 0.25% trypsin/0.53 mM

EDTA in Hank's buffered salt solution without calcium and magnesium.

SKOV-3 Xenograft Mouse Models. All experiments were performed under an Institutional Animal Care and Use Committee-approved protocol, and the experiments followed institutional guidelines for the proper and humane use of animals in research. Six- to eight-week-old athymic nu/nu female mice (NCRNU-M) were obtained from Taconic Farms Incorporated (Hudson, NY). Animals were housed in ventilated cages, given food and water *ad libitum*, and allowed to acclimatize for ~1 week prior to treatment. After several days, SKOV-3 tumors were induced on the right shoulder by a subcutaneous injection of 1.0×10^6 cells in a 100 μL cell suspension of a 1:1 mixture of fresh media/BD Matrigel (BD Biosciences, Bedford, Ma).

^{111}In - and ^{177}Lu -octapa/DOTA-Trastuzumab Biodistribution Studies. Biodistribution studies were used to evaluate the 5 day stability and tumor uptake of the ^{111}In - and ^{177}Lu -octapa-trastuzumab preparations and were compared to the same system using the "gold standard" ^{111}In - and ^{177}Lu -DOTA-trastuzumab. DOTA- and H_4 octapa-trastuzumab constructs were radiolabeled with ^{111}In - and ^{177}Lu under the same conditions as described above and prepared for biodistribution and SPECT/CT imaging studies in nude athymic mice (female, 6–8 weeks old) bearing subcutaneous SKOV-3 ovarian cancer xenografts (HER2-positive, small with tumor volume ~100–150 mm^3). The radiolabeled immunoconjugates were purified via PD-10 size exclusion columns, followed by further purification and concentration via centrifuge filtration (Amicon Ultra centrifuge filters, Ultracel-50: regenerated cellulose, Millipore Corp., Billerica, MA). The purified immunoconjugates were suspended in sterile saline (0.9% NaCl) to a concentration and dose of ~30 μCi (1.1 MBq) in 200 μL per mouse. The specific activity of ^{111}In -octapa-trastuzumab was ~3.7 $\mu\text{Ci}/\mu\text{g}$, and for ^{177}Lu -octapa-trastuzumab it was ~3.3 $\mu\text{Ci}/\mu\text{g}$. The specific activity of ^{111}In -DOTA-trastuzumab was ~2.0 $\mu\text{Ci}/\mu\text{g}$, and for ^{177}Lu -DOTA-trastuzumab it was ~3.4 $\mu\text{Ci}/\mu\text{g}$. The amount of immunoconjugate injected per mouse was ~10–15 μg . Each mouse was intravenously injected through the tail vein and euthanized by CO_2 (g) asphyxiation at time points of 24, 48, 72, 96, and 120 h ($n = 4$ per time point). Organs collected after sacrifice included blood, tumor, heart, lungs, liver, spleen, kidneys, large and small intestines, muscle, bone (femur), and skin (ear). All organs were rinsed in water after removal and air dried for 5 min. Tissues were weighed and counted (calibrated for ^{111}In or ^{177}Lu), the counts were background and decay corrected from the time of injection and then converted to the percentage of injected dose (%ID) per gram of organ tissue (%ID/g). The radioactivity counts measured in each organ were converted to activity (μCi) using a calibration curve created from known standards of ^{111}In or ^{177}Lu .

^{111}In - and ^{177}Lu -octapa/DOTA-Trastuzumab SPECT/CT Imaging Studies. Mice with SKOV-3 ovarian cancer xenografts were imaged with ^{111}In ($n = 2$) and ^{177}Lu ($n = 2$) labeled immunoconjugates, using a four-headed NanoSPECT/CTPLUS camera (Bioscan Inc., Washington, DC, USA) with a multipinhole focused collimator and a temperature control animal bed unit (Minerve Equipment Veterinaire). Nine pinhole apertures with a diameter of 2.5 mm were used on each head, with a field of view (FOV) of 24 mm. Settings of the ^{111}In energy peaks were 245 and 171 keV, and the ^{177}Lu peaks were 208, 112, and 56 keV. A CT at 45 kVp was acquired (180

projections, pitch of 1). Based on the helical CT topogram, SPECT images were obtained over a range of 85 mm. For the octapa-based radioimmunoconjugates, the mice were administered with either ~550 μCi of ^{111}In -octapa-trastuzumab (specific activity ~3.7 $\mu\text{Ci}/\mu\text{g}$) or ~450 μCi of ^{177}Lu -octapa-trastuzumab (3.3 $\mu\text{Ci}/\mu\text{g}$) in 200 μL of sterile saline (0.9% NaCl) via intravenous tail vein injection. For the DOTA-based radioimmunoconjugates, the mice were administered with either ~400 μCi of ^{111}In -DOTA-trastuzumab (specific activity ~2.0 $\mu\text{Ci}/\mu\text{g}$) or ~550 μCi of ^{177}Lu -octapa-trastuzumab (3.4 $\mu\text{Ci}/\mu\text{g}$) in 200 μL of sterile saline (0.9% NaCl) via intravenous tail vein injection. The amount of immunoconjugate injected per mouse was ~150–200 μg . Approximately 5 min prior to SPECT/CT image acquisition, mice were anesthetized via inhalation of 2% isoflurane/oxygen gas mixture (Baxter Healthcare, Deerfield, IL) and placed on the scanner bed. Anesthesia was maintained during imaging using a reduced 1.5% isoflurane/oxygen mixture. Animals were imaged at 24, 48, 72, 96, and 120 h p.i. Mice injected with ^{177}Lu -labeled immunoconjugates were imaged for 1.5–2 h each, and mice injected with ^{111}In -labeled immunoconjugates were imaged for 40 min (24 and 48 h time points), 50 min (72 h), and 60 min (96 and 120 h). Image collection was performed using NuLine software (V1.02 build 009), and images were processed and reconstructed using InVivoScope (2.00 patch3, 64 bit) and HiSPECT (v 1.4.3049) software. To derive the isotope-specific calibration factors, a mouse-sized phantom filled with 1.5–2 mCi of $^{111}\text{InCl}_3$ or $^{177}\text{LuCl}_3$ was scanned.

Cerenkov Luminescence Imaging (CLI). Optical images of CR were obtained using an IVIS 200 (Caliper Life Sciences) optical imaging machine. This system uses a cryo-cooled charge-coupled device for high-sensitivity detection of low-intensity sources. Two minute exposures were obtained of isoflurane anesthetized mice ($n = 2$) 24 h post injection of ~450 μCi of ^{177}Lu -octapa-trastuzumab (3.3 $\mu\text{Ci}/\mu\text{g}$) in 200 μL of sterile saline (0.9% NaCl) via intravenous tail vein injection.

Statistics. All data used was obtained in at least triplicate ($n = 3$), and all values were expressed as mean $\pm$ SD. A student's two-tailed t test was used to compare all biodistribution data sets. A p -value ≤ 0.05 was considered statistically significant. A one-way ANOVA analysis was also performed on select data points; a p -value ≤ 0.05 was considered statistically significant.

■ ASSOCIATED CONTENT

● Supporting Information

Additional SPECT/CT images, selected $^1\text{H}/^{13}\text{C}$ NMR spectra, potentiometric titration data, and select FT-ATR-IR spectra of final synthesized compounds. This information is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

lewisj2@mskcc.org; adam@triumf.ca; orvig@chem.ubc.ca

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was presented at the 2013 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, and the abstract was awarded the Berson-Yalow award. The authors thank Blesida Punzalan for skillful tail-vein injections, Dr. Pat Zanzonico and Valerie A. Longo for aid with SPECT/

CT calibration, Dr. Daniel L. J. Thorek for help with Cerenkov optical imaging, and Michael Doran for cell culture work. We thank Dr. Cara L. Ferreira and Dr. Dennis W. Wester (Nordion) for radiochemistry mentoring and collaboration throughout the project, and Gwendolyn A. Bailey for early synthesis help. We acknowledge Nordion (Canada) and the Natural Sciences and Engineering Research Council (NSERC) of Canada for grant support (CR&D), NSERC for CGS-M/CGS-D fellowships (E.W.P., C.F.R.), and the University of British Columbia for 4YF fellowships (E.W.P., C.F.R.). C.O. acknowledges the Canada Council for the Arts for a Killam Research Fellowship (2011–2013), the University of Canterbury for a Visiting Erskine Fellowship (2013), and the Alexander von Humboldt Foundation for a Research Award, as well as Prof. Dr. Peter Comba and his research group in Heidelberg for hospitality and interesting discussions. Services provided by the MSKCC Small-Animal Imaging Core Facility were supported in part by NIH grants R24 CA83084 and P30 CA08748. The authors also thank the NIH (award 1F32CA1440138-01, B.M.Z.) and the DOE (award DE-SC0002184, J.S.L.) for their generous funding.

REFERENCES

- (1) Rösch, F.; Baum, R. P. *Dalton Trans.* **2011**, 40, 6104–6111.
- (2) Zeglis, B. M.; Lewis, J. S. *Dalton Trans.* **2011**, 40, 6168–6195.
- (3) Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. *Chem. Rev.* **2010**, 110, 2858–2902.
- (4) Deri, M. A.; Zeglis, B. M.; Francesconi, L. C.; Lewis, J. S. *Nucl. Med. Biol.* **2013**, 40, 3–14.
- (5) Zeglis, B. M.; Mohindra, P.; Weissmann, G. I.; Divilov, V.; Hilderbrand, S. A.; Weissleder, R.; Lewis, J. S. *Bioconjugate Chem.* **2011**, 22, 2048–2059.
- (6) Bartholoma, M. D.; Louie, A. S.; Valliant, J. F.; Zubietta, J. *Chem. Rev.* **2010**, 110, 2903–2920.
- (7) Ramogida, C. F.; Orvig, C. *Chem. Commun.* **2013**, 49, 4720–4739.
- (8) Holland, J. P.; Williamson, M. J.; Lewis, J. S. *Mol. Imaging* **2010**, 9, 1–20.
- (9) Holland, J. P.; Divilov, V.; Bander, N. H.; Smith-Jones, P. M.; Larson, S. M.; Lewis, J. S. *J. Nucl. Med.* **2010**, 51, 1293–1300.
- (10) Boswell, C. A.; Brechbiel, M. W. *Nucl. Med. Biol.* **2007**, 34, 757–778.
- (11) Vermeer, A. W. P.; Norde, W. *Biophys. J.* **2000**, 78, 394–404.
- (12) Stimmel, J. B.; Kull, F. C., Jr. *Nucl. Med. Biol.* **1998**, 25, 117–125.
- (13) Stimmel, J. B.; Stockstill, M. E.; Kull, F. C. *Bioconjugate Chem.* **1995**, 6, 219–225.
- (14) Camera, L.; Kinuya, S.; Garmestani, K.; Wu, C.; Brechbiel, M. W.; Pai, L. H.; McMurry, T. J.; Gansow, O. A.; Pastan, I.; Paik, C. H.; Carrasquillo, J. A. *J. Nucl. Med.* **1994**, 35, 882–889.
- (15) Harrison, A.; Walker, C. A.; Parker, D.; Jankowski, K. J.; Cox, J. P. L.; Craig, A. S.; Sansom, J. M.; Beeley, N. R. A.; Boyce, R. A.; Chaplin, L.; Eaton, M. A. W.; Farnsworth, A. P. H.; Millar, K.; Millican, A. T.; Randall, A. M.; Rhind, S. K.; Secher, D. S.; Turner, A. *Int. J. Radiat. Appl. Instrum., Part B* **1991**, 18, 469–476.
- (16) Cooper, M. S.; Ma, M. T.; Sunassee, K.; Shaw, K. P.; Williams, J. D.; Paul, R. L.; Donnelly, P. S.; Blower, P. J. *Bioconjugate Chem.* **2012**, 23, 1029–1039.
- (17) Martell, A. E.; Smith, R. M. *Critical Stability Constants*; Plenum Press: New York, 1974–1989; Vols. 1–6.
- (18) Hancock, R. D. J. *Chem. Educ.* **1992**, 69, 615–621.
- (19) Liu, S.; Pietryka, J.; Ellars, C. E.; Edwards, D. S. *Bioconjugate Chem.* **2002**, 13, 902–913.
- (20) Liu, S.; Edwards, D. S. *Bioconjugate Chem.* **2000**, 12, 7–34.
- (21) Kukis, D. L.; DeNardo, S. J.; DeNardo, G. L.; O'Donnell, R. T.; Meares, C. F. *J. Nucl. Med.* **1998**, 39, 2105–2110.
- (22) Jang, Y. H.; Blanco, M.; Dasgupta, S.; Keire, D. A.; Shively, J. E.; Goddard, W. A. *J. Am. Chem. Soc.* **1999**, 121, 6142–6151.
- (23) Milenic, D. E.; Garmestani, K.; Chappell, L. L.; Dadachova, E.; Yordanov, A.; Ma, D.; Schlom, J.; Brechbiel, M. W. *Nucl. Med. Biol.* **2002**, 29, 431–442.
- (24) Kang, C. S.; Sun, X.; Jia, F.; Song, H. A.; Chen, Y.; Lewis, M.; Chong, H.-S. *Bioconjugate Chem.* **2012**, 23, 1775–1782.
- (25) Chappell, L. L.; Ma, D.; Milenic, D. E.; Garmestani, K.; Venditto, V.; Beitzel, M. P.; Brechbiel, M. W. *Nucl. Med. Biol.* **2003**, 30, 581–595.
- (26) Rasane, S.; Rajabi, H.; Babaei, M. H.; Johari Dahi, F. *J. Labelled Compd. Radiopharm.* **2010**, 53, S75–S79.
- (27) Förster, G. J.; Engelbach, M. J.; Brockmann, J. J.; Reber, H. J.; Buchholz, H. G.; Mäcke, H. R.; Rösch, F. R.; Herzog, H. R.; Bartenstein, P. R. *Eur. J. Nucl. Med.* **2001**, 28, 1743–1750.
- (28) Wu, C.; Kobayashi, H.; Sun, B.; Yoo, T. M.; Paik, C. H.; Gansow, O. A.; Carrasquillo, J. A.; Pastan, I.; Brechbiel, M. W. *Bioorg. Med. Chem.* **1997**, 5, 1925–1934.
- (29) Brechbiel, M. W.; Gansow, O. A.; Atcher, R. W.; Schlom, J.; Esteban, J.; Simpson, D.; Colcher, D. *Inorg. Chem.* **1986**, 25, 2772–2781.
- (30) Boros, E.; Ferreira, C. L.; Cawthray, J. F.; Price, E. W.; Patrick, B. O.; Wester, D. W.; Adam, M. J.; Orvig, C. *J. Am. Chem. Soc.* **2010**, 132, 15726–15733.
- (31) Boros, E.; Ferreira, C. L.; Yapp, D. T. T.; Gill, R. K.; Price, E. W.; Adam, M. J.; Orvig, C. *Nucl. Med. Biol.* **2012**, 39, 785–794.
- (32) Boros, E.; Cawthray, J. F.; Ferreira, C. L.; Patrick, B. O.; Adam, M. J.; Orvig, C. *Inorg. Chem.* **2012**, 51, 6279–6284.
- (33) Price, E. W.; Cawthray, J. F.; Bailey, G. A.; Ferreira, C. L.; Boros, E.; Adam, M. J.; Orvig, C. *J. Am. Chem. Soc.* **2012**, 134, 8670–8683.
- (34) Boros, E.; Lin, Y.-H. S.; Ferreira, C. L.; Patrick, B. O.; Hafeli, U. O.; Adam, M. J.; Orvig, C. *Dalton Trans.* **2011**, 40, 6253–6259.
- (35) Boros, E.; Ferreira, C. L.; Patrick, B. O.; Adam, M. J.; Orvig, C. *Nucl. Med. Biol.* **2011**, 38, 1165–1174.
- (36) Bailey, G. A.; Price, E. W.; Zeglis, B. M.; Ferreira, C. L.; Boros, E.; Lacasse, M. J.; Patrick, B. O.; Lewis, J. S.; Adam, M. J.; Orvig, C. *Inorg. Chem.* **2012**, 51.
- (37) Platas-Iglesias, C.; Mato-Iglesias, M.; Djanashvili, K.; Muller, R. N.; Elst, L. V.; Peters, J. A.; de Blas, A.; Rodríguez-Blas, T. *Chem.—Eur. J.* **2004**, 10, 3579–3590.
- (38) Ferreira-Martinez, R.; Esteban-Gomez, D.; Platas-Iglesias, C.; Blas, A. d.; Rodríguez-Blas, T. *Dalton Trans.* **2008**, 5754–5765.
- (39) Masuda, R.; Oishi, S.; Ohno, H.; Kimura, H.; Saji, H.; Fujii, N. *Bioorg. Med. Chem.* **2011**, 19, 3216–3220.
- (40) Dioury, F.; Guéné, E.; Scala-Rouilleau, A. D.; Ferroud, C.; Guy, A.; Port, M. *Tetrahedron Lett.* **2005**, 46, 611–613.
- (41) Favre-Régouillon, A.; Segat-Dioury, F.; Nait-Bouda, L.; Cosma, C.; Siaugue, J.-M.; Foos, J.; Guy, A. *Synlett* **2000**, 2000, 0868–0871.
- (42) Fukuyama, T.; Jow, C.-K.; Cheung, M. *Tetrahedron Lett.* **1995**, 36, 6373–6374.
- (43) Salvatore, R. N.; Yoon, C. H.; Jung, K. W. *Tetrahedron* **2001**, 57, 7785–7811.
- (44) Viola, N. A.; Rarig, R. S., Jr.; Ouellette, W.; Doyle, R. P. *Polyhedron* **2006**, 25, 3457–3462.
- (45) Tóth, É.; Brücher, E. *Inorg. Chim. Acta* **1994**, 221, 165–167.
- (46) Cacheris, W. P.; Nickle, S. K.; Sherry, A. D. *Inorg. Chem.* **1987**, 26, 958–960.
- (47) Loncin, M. F.; Desreux, J. F.; Merciny, E. *Inorg. Chem.* **1986**, 25, 2646–2648.
- (48) Andereg, G.; Arnaud-Neu, F.; Delgado, R.; Felcman, J.; Popov, K. *Pure Appl. Chem.* **2005**, 77, 1445–1495.
- (49) Šimeček, J.; Schulz, M.; Notni, J.; Plutnar, J.; Kubíček, V.; Havlíčková, J.; Hermann, P. *Inorg. Chem.* **2011**, 51, 577–590.
- (50) Šimeček, J.; Hermann, P.; Wester, H.-J.; Notni, J. *ChemMedChem* **2013**, 8, 95–103.
- (51) Thorek, D. L. J.; Abou, D. S.; Beattie, B. J.; Bartlett, R. M.; Huang, R.; Zanzonico, P. B.; Grimm, J. *J. Nucl. Med.* **2012**, 53, 1438–1445.
- (52) Kumar Mishra, A.; Panwar, P.; Chopra, M.; Kumar Sharma, R.; Chatal, J.-F. *New J. Chem.* **2003**, 27, 1054–1058.
- (53) Gran, G. *Analyst* **1952**, 77, 661–671.

- (54) Duckworth, P. *Private communication*.
- (55) Gans, P.; Sabatini, A.; Vacca, A. *Talanta* **1996**, *43*, 1739–1753.
- (56) Baes, C. F., Jr.; Mesmer, R. E. Wiley-Interscience: New York, 1976.
- (57) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Ö. Farkas, Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. *Gaussian 09*, Revision A.1, Gaussian, Inc.: Wallingford CT, 2009.
- (58) Lee, C.; Yang, W.; Parr, R. G. *Phys. Rev. B* **1988**, *37*, 785–789.
- (59) Becke, A. D. *J. Chem. Phys.* **1993**, *98*, 5648–5652.
- (60) Cao, X.; Dolg, M. *J. Chem. Phys.* **2001**, *115*, 7348–7355.
- (61) Holland, J. P.; Caldas-Lopes, E.; Divilov, V.; Longo, V. A.; Taldone, T.; Zatorska, D.; Chiosis, G.; Lewis, J. S. *PLoS One* **2010**, *5*, e8859.
- (62) Anderson, C. J.; Connett, J. M.; Schwarz, S. W.; Rocque, P. A.; Guo, L. W.; Philpott, G. W.; Zinn, K. R.; Meares, C. F.; Welch, M. J. *J. Nucl. Med.* **1992**, *33*, 1685–1691.
- (63) Anderson, C. J.; Schwarz, S. W.; Connett, J. M.; Cutler, P. D.; Guo, L. W.; Germain, C. J.; Philpott, G. W.; Zinn, K. R.; Greiner, D. P.; Meares, C. F.; Welch, M. J. *J. Nucl. Med.* **1995**, *36*, 850–858.
- (64) Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P. A., Jr. *J. Immunol. Methods* **1984**, *72*, 77–89.
- (65) Lindmo, T.; Bunn, P. A., Jr. *Methods Enzymol.* **1986**, *121*, 678–691.